Rf Kefford
Professor
Department, Clinical Medicine, Faculty of Medicine and Healt
Macquarie University
Australia
Biography
Professor Richard Kefford AM MB BS PhD FRACP is Professor of Cancer Medicine and Head, Department of Clinical Medicine at Macquarie University, Sydney and Co-Director of Research at Melanoma Institute Australia. He is an internationally acclaimed melanoma researcher and a national leader in academic medicine and medical research with a life-long record of commitment and service to Australian medical research, peer review, professional training and mentoring and community education in oncology. He contributed to the mapping and characterisation of the major melanoma susceptibility genes and the development of international guidelines on genetic testing of those at high melanoma risk. He played a pivotal role in the development of life-extending drug treatments now used as standard-of-care for melanoma, including the first-time in human trial of dabrafenib, the pioneering use of dabrafenib and trametinib for patients with brain metastases, and the Phase 1 clinical trial of pembrolizumab.
Research Interest
Cancer Medicine, care for melanoma
Publications
-
Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases Parakh, S., Park, J. J., Mendis, S., Rai, R., Xu, W., Lo, S., Drummond, M., Rowe, C., Wong, A., McArthur, G., Haydon, A., Andrews, M. C., Cebon, J., Guminski, A., Kefford, R. F., Long, G. V., Menzies, A. M., Klein, O. & Carlino, M. S. 6 Jun 2017 In : British Journal of Cancer. 116, 12, p. 1558-1563 6 p.
